-
3
-
-
85058694585
-
-
Fact Sheet [homepage on the internet]. World Health Organization. Available from:, Accessed June 1, 2017
-
Hepatitis C Fact Sheet [homepage on the internet]. World Health Organization. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed June 1, 2017.
-
-
-
Hepatitis, C.1
-
4
-
-
84874104840
-
Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland
-
Mcdonald SA, Hutchinson SJ, Palmateer NE, et al. Decrease in health-related quality of life associated with awareness of hepatitis C virus infection among people who inject drugs in Scotland. J Hepatol. 2013; 58(3):460–466.
-
(2013)
J Hepatol
, vol.58
, Issue.3
, pp. 460-466
-
-
McDonald, S.A.1
Hutchinson, S.J.2
Palmateer, N.E.3
-
5
-
-
84155174944
-
Health utilities and psychometric quality of life in patients with early-and late-stage hepatitis C virus infection
-
Hsu PC, Federico CA, Krajden M, et al. Health utilities and psychometric quality of life in patients with early-and late-stage hepatitis C virus infection. J Gastroenterol Hepatol. 2012;27(1):149–157.
-
(2012)
J Gastroenterol Hepatol
, vol.27
, Issue.1
, pp. 149-157
-
-
Hsu, P.C.1
Federico, C.A.2
Krajden, M.3
-
6
-
-
84922855628
-
Systematic review: Patient-reported outcomes in chronic hepatitis C – the impact of liver disease and new treatment regimens
-
Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C – the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41(6):497–520.
-
(2015)
Aliment Pharmacol Ther
, vol.41
, Issue.6
, pp. 497-520
-
-
Younossi, Z.1
Henry, L.2
-
7
-
-
0035133564
-
Hepatitis Interventional Therapy Group. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity
-
McHutchison JG, Ware JE, et al; Hepatitis Interventional Therapy Group. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol. 2001;34(1):140–147.
-
(2001)
J Hepatol
, vol.34
, Issue.1
, pp. 140-147
-
-
McHutchison, J.G.1
Ware, J.E.2
-
8
-
-
12144288357
-
The impact of peginter-feron alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C
-
Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginter-feron alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol. 2004;40(4):675–681.
-
(2004)
J Hepatol
, vol.40
, Issue.4
, pp. 675-681
-
-
Hassanein, T.1
Cooksley, G.2
Sulkowski, M.3
-
9
-
-
84904730054
-
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study
-
Younossi ZM, Stepanova M, Zeuzem S, et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol. 2014;61(2):228–234.
-
(2014)
J Hepatol
, vol.61
, Issue.2
, pp. 228-234
-
-
Younossi, Z.M.1
Stepanova, M.2
Zeuzem, S.3
-
10
-
-
84896404567
-
Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C)
-
Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol. 2014;60(4):741–747.
-
(2014)
J Hepatol
, vol.60
, Issue.4
, pp. 741-747
-
-
Younossi, Z.M.1
Stepanova, M.2
Henry, L.3
-
11
-
-
85012013989
-
Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: Current knowledge and outstanding issues
-
Marcellin F, Roux P, Protopopescu C, Duracinsky M, Spire B, Carrieri MP. Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Rev Gastroenterol Hepatol. 2017;11(3):1–10.
-
(2017)
Expert Rev Gastroenterol Hepatol
, pp. 1-10
-
-
Marcellin, F.1
Roux, P.2
Protopopescu, C.3
Duracinsky, M.4
Spire, B.5
Carrieri, M.P.6
-
12
-
-
84904399630
-
Incorporating patient-reported outcomes into hepatitis C virus treatment studies
-
Evon DM. Incorporating patient-reported outcomes into hepatitis C virus treatment studies. Clin Gastroenterol Hepatol. 2014;12(8): 1360–1362.
-
(2014)
Clin Gastroenterol Hepatol
, vol.12
, Issue.8
, pp. 1360-1362
-
-
Evon, D.M.1
-
13
-
-
84979988396
-
Adherence to treatment of chronic hepatitis C: From interferon containing regimens to interferon and ribavirin free regimens
-
Younossi ZM, Stepanova M, Henry L, Nader F, Younossi Y, Hunt S. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. Medicine. 2016;95(28):e4151.
-
(2016)
Medicine
, vol.95
, Issue.28
-
-
Younossi, Z.M.1
Stepanova, M.2
Henry, L.3
Nader, F.4
Younossi, Y.5
Hunt, S.6
-
14
-
-
6044272647
-
Initial treatment for chronic hepatitis C: Current therapies and their optimal dosing and duration
-
Patel K, Mchutchison JG. Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. Cleve Clin J Med. 2004;71(Suppl 3):S8–S12.
-
(2004)
Cleve Clin J Med
, vol.71
, pp. S8-S12
-
-
Patel, K.1
McHutchison, J.G.2
-
15
-
-
2342418781
-
Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice
-
Shehab TM, Fontana RJ, Oberhelman K, Marrero JA, Su GL, Lok AS. Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol. 2004;2(5):425–431.
-
(2004)
Clin Gastroenterol Hepatol
, vol.2
, Issue.5
, pp. 425-431
-
-
Shehab, T.M.1
Fontana, R.J.2
Oberhelman, K.3
Marrero, J.A.4
Su, G.L.5
Lok, A.S.6
-
16
-
-
84886028561
-
Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: A literature review
-
Mravčík V, Strada L, Stolfa J, et al. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence. 2013;7: 1067–1075.
-
(2013)
Patient Prefer Adherence
, vol.7
, pp. 1067-1075
-
-
Mravčík, V.1
Strada, L.2
Stolfa, J.3
-
17
-
-
34748883705
-
Understanding the minimum clinically important difference: A review of concepts and methods
-
Copay AG, Subach BR, Glassman SD, Polly DW, Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J. 2007;7(5):541–546.
-
(2007)
Spine J
, vol.7
, Issue.5
, pp. 541-546
-
-
Copay, A.G.1
Subach, B.R.2
Glassman, S.D.3
Polly, D.W.4
Schuler, T.C.5
-
18
-
-
0024852022
-
Measurement of health status. Ascertaining the minimal clinically important difference
-
Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10(4):407–415.
-
(1989)
Control Clin Trials
, vol.10
, Issue.4
, pp. 407-415
-
-
Jaeschke, R.1
Singer, J.2
Guyatt, G.H.3
-
19
-
-
84994718632
-
Efficacy and safety of elbasvir/ grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial
-
Sperl J, Horvath G, Halota W, et al. Efficacy and safety of elbasvir/ grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial. J Hepatol. 2016;65(6):1112–1119.
-
(2016)
J Hepatol
, vol.65
, Issue.6
, pp. 1112-1119
-
-
Sperl, J.1
Horvath, G.2
Halota, W.3
-
20
-
-
0034671279
-
SF-36 health survey update
-
Ware JE. SF-36 health survey update. Spine. 2000;25(24):3130–3139.
-
(2000)
Spine
, vol.25
, Issue.24
, pp. 3130-3139
-
-
Ware, J.E.1
-
21
-
-
0028120266
-
The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups
-
Mchorney CA, Ware JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40–66.
-
(1994)
Med Care
, vol.32
, Issue.1
, pp. 40-66
-
-
McHorney, C.A.1
Ware, J.E.2
Lu, J.F.3
Sherbourne, C.D.4
-
22
-
-
16244391099
-
Impact of hepatitis C on health related quality of life: A systematic review and quantitative assessment
-
Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41(4):790–800.
-
(2005)
Hepatology
, vol.41
, Issue.4
, pp. 790-800
-
-
Spiegel, B.M.1
Younossi, Z.M.2
Hays, R.D.3
Revicki, D.4
Robbins, S.5
Kanwal, F.6
-
23
-
-
68949212487
-
Quality of life considerations for patients with chronic hepatitis C
-
Foster GR. Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat. 2009;16(9):605–611.
-
(2009)
J Viral Hepat
, vol.16
, Issue.9
, pp. 605-611
-
-
Foster, G.R.1
-
24
-
-
84961891957
-
An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis c treated with different anti-viral regimens
-
Younossi ZM, Stepanova M, Henry L, Nader F, Hunt S. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis c treated with different anti-viral regimens. Am J Gastroenterol. 2016; 111(6):808–816.
-
(2016)
Am J Gastroenterol
, vol.111
, Issue.6
, pp. 808-816
-
-
Younossi, Z.M.1
Stepanova, M.2
Henry, L.3
Nader, F.4
Hunt, S.5
-
25
-
-
84990989646
-
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and-3 Clinical Trials
-
Younossi ZM, Stepanova M, Sulkowski M, et al. Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and-3 Clinical Trials. Clin Infect Dis. 2016;63(8):1042–1048.
-
(2016)
Clin Infect Dis
, vol.63
, Issue.8
, pp. 1042-1048
-
-
Younossi, Z.M.1
Stepanova, M.2
Sulkowski, M.3
-
26
-
-
85013650566
-
Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity
-
Younossi ZM, Stepanova M, Esteban R, et al. Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity. Medicine. 2017;96(7):e5914.
-
(2017)
Medicine
, vol.96
, Issue.7
-
-
Younossi, Z.M.1
Stepanova, M.2
Esteban, R.3
-
27
-
-
84964678998
-
Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial
-
Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016;65(1):33–39.
-
(2016)
J Hepatol
, vol.65
, Issue.1
, pp. 33-39
-
-
Younossi, Z.M.1
Stepanova, M.2
Feld, J.3
-
28
-
-
84936849320
-
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir
-
Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015;63(2):337–345.
-
(2015)
J Hepatol
, vol.63
, Issue.2
, pp. 337-345
-
-
Younossi, Z.M.1
Stepanova, M.2
Afdhal, N.3
-
29
-
-
0030898261
-
Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system
-
Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63–74.
-
(1997)
J Pain Symptom Manage
, vol.13
, Issue.2
, pp. 63-74
-
-
Yellen, S.B.1
Cella, D.F.2
Webster, K.3
Blendowski, C.4
Kaplan, E.5
-
30
-
-
85019692409
-
Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study
-
Younossi ZM, Stepanova M, Sulkowski M, Wyles D, Kottilil S, Hunt S. Patient-reported outcomes in patients co-infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL-5 study. Liver Int. 2017;37(12):1796–1804.
-
(2017)
Liver Int
, vol.37
, Issue.12
, pp. 1796-1804
-
-
Younossi, Z.M.1
Stepanova, M.2
Sulkowski, M.3
Wyles, D.4
Kottilil, S.5
Hunt, S.6
-
32
-
-
0036186518
-
Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients
-
Bernstein D, Kleinman L, Barker CM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002; 35(3):704–708.
-
(2002)
Hepatology
, vol.35
, Issue.3
, pp. 704-708
-
-
Bernstein, D.1
Kleinman, L.2
Barker, C.M.3
Revicki, D.A.4
Green, J.5
-
33
-
-
85058691471
-
-
Available from:, Accessed September 21, 2017
-
Maistat L, Golovin S, Kravchenko N, Kahn T, Babikhina K. Hepatitis C in Eastern Europe and Central Asia. Civil Society Response to the Epidemic; 2016. Available from: http://aph.org.ua/wp-content/uploads/2016/07/EECA_HCV_2016_EN.pdf. Accessed September 21, 2017.
-
(2016)
Hepatitis C in Eastern Europe and Central Asia. Civil Society Response to the Epidemic
-
-
Maistat, L.1
Golovin, S.2
Kravchenko, N.3
Kahn, T.4
Babikhina, K.5
-
34
-
-
85049206640
-
Hepatitis C in Eastern Europe and Central Asia: A survey of epidemiology, treatment access and civil society activity in eleven countries
-
Maistat L, Kravchenko N, Reddy A. Hepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries. Hepatol Med Policy. 2016;2(1):9.
-
(2016)
Hepatol Med Policy
, vol.2
, Issue.1
, pp. 9
-
-
Maistat, L.1
Kravchenko, N.2
Reddy, A.3
|